Vanda Pharmaceuticals

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 5 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

7 drugs in development

Approved2

Phase 35

Phase 25

Phase 11

By Therapeutic Area

top 6

Psychiatry

427%

Gastroenterology

320%

Immunology

213%

Nephrology

17%

Infectious Disease

17%

Cardiovascular

17%

R&D Momentum

56/100

Pipeline Velocity

25/100

Trial Completion Rate

91/100

Pipeline Concentration

16/100

Pipeline Freshness

70/100

Strategic Signals

↗Active in Nephrology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 26, 2026TrialA Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Acute Anxiety in Patients With Social Anxiety Disorder

Feb 25, 2026TrialA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Feb 20, 2026FDABysanti — BYSANTI

Jan 1, 2026TrialOpen Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Dec 30, 2025FDANereus — NEREUS

Oct 1, 2025TrialAn Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Sep 15, 2025TrialEvaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

May 14, 2025TrialRandomized Withdrawal Study in Patients With Schizophrenia

3 more events

May 13, 2025TrialTreatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient

May 5, 2025TrialSafety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

Apr 21, 2025TrialEvaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

16 patent groups across drugs · Source: FDA Orange Book

DrugExpires

FanaptNov 2, 2027 BysantiMar 28, 2028 PonvoryNov 16, 2029 Fanapt5 patentsApr 5, 2030 BysantiJul 24, 2030 Fanapt3 patentsJan 16, 2031 PonvoryMay 6, 2032 Hetlioz18 patentsJan 25, 2033

8 more

Hetlioz4 patentsMay 17, 2034 Hetlioz8 patentsFeb 12, 2035 Ponvory2 patentsDec 10, 2035 Nereus4 patentsMar 4, 2036 Hetlioz2 patentsDec 11, 2040 HetliozFeb 21, 2041 PonvoryOct 10, 2042 BysantiMay 31, 2044

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

—

Cardiovascular(1 drug)

Gastroenterology(3 drugs)

—

Gastroenterology(3 drugs)

Immunology(2 drugs)

—

Immunology(2 drugs)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Nephrology(1 drug)

—

Nephrology(1 drug)

Neurology(1 drug)

—

Neurology(1 drug)

Psychiatry(4 drugs)

—

Psychiatry(4 drugs)

Unknown / Other(2 drugs)

—

Unknown / Other(2 drugs)

Regulatory

Regulatory Timeline

20091 event

FDAMay 6

Fanapt — FANAPT

Application NDA022192 (NDA)

20141 event

FDAJan 31

Hetlioz — HETLIOZ

Application NDA205677 (NDA)

20201 event

FDADec 1

Hetlioz — HETLIOZ LQ

Application NDA214517 (NDA)

20211 event

FDAMar 18

Ponvory — PONVORY

Application NDA213498 (NDA)

20251 event

FDADec 30

Nereus — NEREUS

Application NDA220152 (NDA)

20261 event

FDAFeb 20

Bysanti — BYSANTI

Application NDA220358 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)